Skip to content

Efficacy and safety of Niaoqingshu granules in the treatment of chronic pelvic pain syndrome(syndrome of dampness-heat diffusing downward)

Efficacy and safety of Niaoqingshu granules in the treatment of chronic pelvic pain syndrome(syndrome of dampness-heat diffusing downward)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005579
Enrollment
Unknown
Registered
2022-02-01
Start date
2011-03-03
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pelvic pain syndrome(syndrome of dampness-heat diffusing downward)

Interventions

observation group:Niaoqingshu granules
control group:Qianliexian capsule

Sponsors

The First Affiliated Hospital of Tianjin University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1) Meet the western diagnostic criteria of non-bacterial CP and TCM syndrome differentiation criteria of dampness-heat syndrome; 2) 18 to 50 years old; 3) The course of disease is not less than 3 months; 4) No prostatitis drugs were used in nearly 2 weeks before inclusion; 5) Informed consent, voluntary subjects; 6) The process of obtaining informed consent conforms to the drug clinical trial Management Code (GCP).

Exclusion criteria

Exclusion criteria: ? Renal function and liver function indexes are above 50% of the upper limit of normal value; ? Patients with serious primary diseases, including lung diseases, hematological diseases and cardiovascular diseases, or AIDS and tumors; ? Have a history of pelvic surgery, severe neurosis, seminal vesiculitis, prostate tumor, benign prostatic hyperplasia, epididymitis, urinary tract diseases and diabetes, etc. (4) mentally ill or disabled; ? Allergic to the test drug or allergic constitution; ? By non-prostatitis caused by lumbosacral, perineum and lower abdomen and other painful diseases; ? Bacterial CP and acute prostatitis; (8) those who have or are suspected of drug or alcohol abuse; ? Applicants who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
odynuria;pollakisurie;Harnzwang;

Countries

China

Contacts

Public Contactjinhua He
huameng876@yeah.net13821820876

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026